Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain.
Miguel Torralba González de SusoGema RodríguezFrancisco Javier González GascaFernando CuadraJosé BarberáPaloma GeijoAndrea SilvaMaría Isabel GarcíaMarcos Alexander OstaizaAna María García PérezEsther ArroyoJuan Ramón LarrubiaAlmudena GutiérrezMaría Lourdes PorrasHenar Calvo SánchezJulia Peña-AsensioJulio Gabriel AriasInés MendozaPublished in: The Annals of pharmacotherapy (2023)
Our real-life data showed that BIC/FTC/TAF is effective and safe for use in the treatment of both TN and TE patients in clinical practice.
Keyphrases
- clinical practice
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- prognostic factors
- patient reported outcomes
- clinical trial
- study protocol
- electronic health record
- peritoneal dialysis
- antiretroviral therapy
- randomized controlled trial
- big data
- patient reported
- double blind
- artificial intelligence
- deep learning